08 Mar Exciting update RAPID-1 Diabetic Foot Ulcer
Biotherapy Services Limited
RAPID-1 Diabetic Foot Ulcer [RAPID-1DFU] Randomised Controlled Trial
The Board and Executive Management Team are delighted to announce that the treatment of patients has commenced on the RAPID-1DFU trial.
The RAPID Biodynamic Haematogel treatment is the first-in-class, medicinal product under development for the treatment of complex and chronic wounds. The RAPID treatment is a novel point-of-care medicine manufactured at the patient’s bedside under strict GMP pharmaceutical manufacturing standards which ensures the quality, consistency and reproducibility of the RAPID Biodynamic Haematogel treatment.
The Chief Investigator of the RAPID-1DFU study is Mr Sandip Sarkar MA PhD FRCS, a Consultant Vascular Surgeon at the BARTS NHS Trust. He is the Clinical Governance Lead and also the Lead for the Vascular Diabetic Multidisciplinary Foot Team at The Royal London Hospital. Mr Sarkar has extensive expertise in the management of complex wounds, particularly with the use of autologous biotherapeutic treatments.
For further information, please contact:
Biotherapy Services Ltd
Janet Hadfield, Chief Executive Officer
Info@biotherapyservices.comTel: ++44 (0) 207 788 7828